Physician profile
Carrie Erdner
NPI 1578924304
$893.94
in general payments reported to CMS, 2019-2025
11 companies · $69.93 in 2025
The $69.93 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $284 · 2023: $310 · 2024: $74.93 · 2025: $69.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $500.35 | 2022-2025 | Proclaim, Eterna |
| Collegium Pharmaceutical, INC. | $115.02 | 2021-2023 | Xtampza |
| Abbvie INC. | $73.61 | 2023-2025 | |
| Protega Pharmaceutials INC | $44.42 | 2023 | Roxybond |
| Medtronic, INC. | $43.14 | 2021-2023 | Intellis Adaptivestim |
| Almatica Pharma LLC | $34.55 | 2021-2022 | |
| Redhill Biopharma INC. | $22.00 | 2021 | |
| Averitas Pharma INC. | $21.16 | 2023 | Qutenza |
| Tersera Therapeutics LLC | $14.47 | 2021 | |
| Biodelivery Sciences International, INC. | $13.30 | 2021 | |
| Ibsa Pharma INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Erdner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.